has completed the acquisition of all of the issued capital of bioanalytical firm Agilex Biolabs, which is valued at $301.3 million.
Back in December, Healius said it viewed the deal as a long-term strategic acquisition that would provide the company with a platform for growth into the global clinical trials sector.
“We see Agilex as a natural fit into our existing pathology business and a logical entry point to the fast-growing global bioanalytical laboratory services market," said Healius’ chief executive officer Malcolm Parmenter.
“With all its scientists and staff joining us today, I extend a warm welcome to Agilex as it becomes an integral part of Healius pathology and of our future growth plan."
Shares in Healius (ASX:HLS)
are trading 0.3 per cent higher at $4.46.